Medindia
About ▼ Careers Internship MedBlog Contact us
English (US) ▼
Medindia
LOGIN REGISTER
Advertisement

The Italian R&D Excellence at the American Urological Association's 2019 Annual Meeting

Saturday, May 4, 2019 General News
Advertisement
Preliminary data show Oncofid®P-B is very well tolerated and has promising efficacy when administered for up to 12 consecutive weeks in BCG unresponsive/intolerant patients with bladder carcinoma in situ (CIS)

Sponsored Post and Backlink Submission


Latest Press Release on General News

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short
More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...
Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer
The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...
A 2017 Hyundai Elantra and 760,000 kilometres of life-saving blood donation deliveries
Mr. Tim German's 2017 Hyundai Elantra a.k.a. "Dark Angel," was bought new from Steele Hyundai Halifax and now has more than 760,000 kilometres on the odometer. With his Elantra, Mr....
Philips Respironics Reaches Agreement with US Government on a Consent Decree Creating a Clear Path Forward
April 10, 2024 Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips’ subsidiaries Philips Holding USA ...
Dr. Andres Bustillo Responds to Miami's Growing Interest in Facelift Procedures
In response to the growing demand for facelifts in Miami , Dr. Andres Bustillo , a renowned board-certified facial plastic surgeon, is offering advanced and time-proven techniques in f...
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close